Cilofexor

Cilofexor
Clinical data
ATC code	None;
Identifiers
	IUPAC name 2-[3-[2-chloro-4-[ [ 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid;
CAS Number	1418274-28-8;
PubChem CID	71228883;
IUPHAR/BPS	10644;
DrugBank	15168 DB 15168;
ChemSpider	68007315;
UNII	YUN2306954;
ChEMBL	ChEMBL4297613;
Chemical and physical data
Formula	C28H22Cl3N3O5
Molar mass	586.85 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl;
	InChI InChI=InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36); Key:KZSKGLFYQAYZCO-UHFFFAOYSA-N;

Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH),^[1]^[2]^[3] and primary sclerosing cholangitis (PSC).^[4]^[5] It is being investigated for use alone or in combination with firsocostat, selonsertib,^[1] or semaglutide.^[2]^[6] In rat models^[3] and human clinical trials^[7] of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury.^[4]